Skip to main content
. 2023 Jan 31;13(3):574. doi: 10.3390/nano13030574

Table 3.

Advantages of nanobodies relevant to developing therapeutics.

1 Highly stable and able to bind antigens with nanomolar affinity
2 High target specificity and lower inherent toxicity
3 It can be humanized
4 Combine the advantage of conventional antibodies with essential features of small molecule drugs
5 Able to address therapeutic targets not easily recognized by conventional antibodies (e.g., the active site of enzyme)
6 Administrated by routes other than intravenous administration
7 Produced cost-effectively on a large scale
8 Extremely lower immunogenic potential
9 Ability to cross the human blood–brain barrier to reach targets in the brain